替吉奥单药三线治疗转移性乳腺癌的临床效果  

Clinical effect of tegeol sigiol in the third-line treatment of metastatic breast cancer

作　　者：满孝蕊 MAN Xiaorui(Department of Oncology,Jinan Integrated Traditional Chinese and Western Medicine Hospital,Shandong Province,Jinan 271100,China)

机构地区：[1]济南市中西医结合医院肿瘤三科,271100

出　　处：《临床合理用药杂志》2023年第22期15-17,23,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察替吉奥单药三线治疗转移性乳腺癌的临床效果。方法选取2020年1月—2021年7月济南市中西医结合医院收治的转移性乳腺癌患者83例,采取随机盲选方式分为试验组41例与参照组42例。参照组患者实施常规药物治疗,试验组患者实施替吉奥治疗。比较2组患者临床疗效,治疗前后肿瘤标志物水平、免疫功能指标、Ki-67、血清指标及不良反应。结果试验组患者的客观缓解率及临床受益率均高于参照组(P<0.05或P<0.01)。治疗后,2组患者癌胚抗原(CEA)、糖类抗原125(CA125)及多肽特异性抗原(TPS)均低于治疗前,且试验组均低于参照组(P<0.01);治疗后,2组患者CD3^(+)及CD4^(+)均高于治疗前,CD8^(+)低于治疗前,且试验组升高/降低幅度大于参照组(P<0.05或P<0.01);治疗后,2组患者Ki-67、血管内皮生长因子(VEGF)及缺氧诱导因子-1α(HIF-1α)均低于治疗前,且试验组均低于参照组(P<0.01)。试验组不良反应总发生率为19.51%,低于参照组的42.86%(χ^(2)=5.255,P=0.021)。结论替吉奥单药三线治疗转移性乳腺癌的效果确切,具有较高的疾病控制率和缓解率,可有效降低肿瘤标志物水平,提升机体免疫力,耐受度更高,可在临床广泛应用。Objective To observe the clinical effect of tegeol sigiol in the third-line treatment of metastatic breast cancer.Methods From January 2020 to July 2021,83 patients with metastatic breast cancer who were admitted to Jinan Integrated Traditional Chinese and Western Medicine Hospital were randomly and blindly divided into the test group of 41 cases and the reference group of 42 cases.The patients in the reference group were treated with conventional drugs,and the patients in the test group were treated with tegeol.The clinical efficacy,tumor markers level,immune function index,Ki-67,serum index before and after treatment and adverse reactions of the two groups were compared.Results The objective remission rate and clinical benefit rate of patients in the test group were higher than those in the reference group(P<0.05 or P<0.01).After treatment,the carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and peptide specific antigen(TPS)of patients in the two groups were lower than those before treatment,and the test group were lower than the reference group(P<0.01);After treatment,the CD3^(+)and CD4^(+)in the two groups were higher than those before treatment,and the CD8^(+)was lower than that before treatment,and the increase/decrease in the test group were greater than those in the reference group(P<0.05 or P<0.01);After treatment,the Ki-67,vascular endothelial growth factor(VEGF)and hypoxia inducible factor-1α(HIF-1α)in the two groups were lower than those before treatment,and the test group were lower than the reference group(P<0.01).The total incidence of adverse reactions in the test group was 19.51%,significantly lower than 42.86%in the reference group(χ^(2)=5.255,P=0.021).Conclusion Tegeol sigiol in the third-line treatment of metastatic breast cancer is effective,with high disease control rate and remission rate,it can effectively reduce the level of tumor markers,improve the immunity of the body,and has higher tolerance,it can be widely used in clinical practice.

关 键 词：转移性乳腺癌 替吉奥单药三线 临床效果 肿瘤标志物 免疫功能 

分 类 号：R737.9[医药卫生—肿瘤]